Premium
Gastric cancer—surgical approach
Author(s) -
Weese James L.,
Nussbaum Michael L.
Publication year - 1992
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2900100107
Subject(s) - medicine , etoposide , chemotherapy , cancer , radiation therapy , lymphovascular invasion , surgery , neoadjuvant therapy , stomach , disease , lymphatic system , incidence (geometry) , oncology , metastasis , breast cancer , pathology , physics , optics
Although the incidence of carcinoma of the stomach has steadily declined over the last 50 years. approximately 23 200 new cases will be diagnosed in the United States this year and 13 700 patients will die. Despite marked improvement in operative techniques, fewer than 20 per cent of those diagnosed with gastric cancer beyond the most superficial levels of invasion will survive for over five years. Gastric tumours spread by local, lymphatic, and aggressive intra‐peritoneal routes as well as hematogenous dissemination. Over 87 per cent of recurrences have local or regional components. Radiation therapy may decrease local and regional recurrences in those patients with transmural tumours. The neoadjuvant use of etoposide, adriamycin, and platinum may yield complete clinical and pathologic responses in patients found to have ‘unresectable’ tumours. Other chemotherapy regimens have been shown to have some effect on advanced disease and may have a role in the neoadjuvant setting. Our current recommendations for the treatment of gastric cancer in a controlled trial setting would be neoadjuvant chemotherapy followed by R 2 resection, postoperative intraoperative radiation therapy with the possibility of postoperative ± chemotherapy. Hopefully, this aggressive multimodality approach will significantly improve the five year survival for this disease.